Our very first patient is officially enrolled into the High Risk arm of the RIDDLE-M-X trial!

RIDDLE-M-X utilises a risk and response adapted approach to treat patients with newly-diagnosed MM who are eligible to undergo an ASCT. 

Please click here for more information, or e-mail us at amarc@alfred.org.au.